Business
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales o...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Transaction adds another innovative rare disease therapy to DRI's expanding portfolio –\n \n \n \n \n – Deal structure offers risk sharing with milestone payments for positive performance –\n \n \n \n \n – Long-term patent-protected exclusivity extends DRI's cash flows –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Nov. 28, 2022\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN), (TSX: DHT.U) (\"DRI\" or \"the Trust\") today announced that a wholly-owned subsidiary of DRI has acquired a royalty interest in worldwide sales of Xenpozyme (olipudase alfa) for a purchase price of\n \n US$30 million\n \n . Additional performance-based milestones of up to\n \n US$26.5 million\n \n may be paid should the sales of the drug outperform expectations.\n \n \n Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (\"ASMD\"), also known as Niemann-Pick disease, in pediatric and adult patients. Xenpozyme was approved in\n \n Japan\n \n in\n \n March 2022\n \n , by the European Commission in\n \n June 2022\n \n , and by the U.S. Food and Drug Administration (\"FDA\") in\n \n August 2022\n \n . There are no other products currently known to be in development for the treatment of ASMD. Xenpozyme is marketed worldwide by Sanofi S.A. (\"Sanofi\"). ASMD is an extremely rare, progressive genetic disease with significant morbidity and mortality, especially among infants and children. Signs and symptoms of ASMD may include enlarged spleen or liver, difficulty breathing, lung infections, and unusual bruising or bleeding, among other disease manifestations. Current management of the disease includes palliative and supportive care to manage the sympto...